Clinical Trends for December 2015

Ryan Syrek


January 01, 2016

Clinical Trend of the Week (December 5-11): Portrazza

Once again, the approval of a promising new drug resulted in the top search term of the week. Necitumumab (Portrazza®) was approved by the US Food and Drug Administration to be used in combination with two forms of chemotherapy: gemcitabine and cisplatin. Patients with metastatic squamous non-small cell lung cancer (NSCLC) who have not previously been treated can now use this combination therapy. In the SQUIRE trial, median overall survival improved by 1.6 months when necitumumab was included in the treatment regimen with the other chemotherapy drugs. Considering that the 5-year survival rate is less than 5% for this condition, clinicians are no doubt eager for any treatment option that may provide patients more time.

For more in-depth clinical information, see Non–Small Cell Lung Cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.